BRIC Countries (Brazil, Russia, India, China) Generics Market Summary, Competitive Analysis and Forecast to 2027
Summary
The BRIC Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2018-22, and forecast to 2027). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the generics industry and had a total market value of $144,339.7 million in 2022. China was the fastest growing country with a CAGR of 14.1% over the 2018-22 period.
Within the generics industry, China is the leading country among the BRIC nations with market revenues of $111,666.9 million in 2022. This was followed by India, Russia and Brazil with a value of $17,617.5, $11,917.6, and $3,137.6 million, respectively.
China is expected to lead the generics industry in the BRIC nations with a value of $171,144.4 million in 2027, followed by India, Russia, Brazil with expected values of $26,308.6, $18,326.1 and $4,730.2 million, respectively.
Scope
Save time carrying out entry-level research by identifying the size, growth, and leading players in the BRIC generics market
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the BRIC generics market
Leading company profiles reveal details of key generics market players’ BRIC operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the BRIC generics market with five year forecasts by both value and volume
Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country
Reasons to Buy
What was the size of the BRIC generics market by value in 2022?
What will be the size of the BRIC generics market in 2027?
What factors are affecting the strength of competition in the BRIC generics market?
How has the market performed over the last five years?
How large is the BRIC generics market in relation to its regional counterparts?